TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37870228
Drug: PB-IORT (Precision
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-IORT (Precision breast intraoperative radiation therapy) with customized CT-based HDR brachytherapy.
Study: 37870510
Drug: Nonhormonal selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonhormonal selective NK3R antagonist
Study: 39261417
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg once every 3 weeks
Study: 37870862
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg per day maximum-tolerated dose)
Study: 37870954
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen citrate, 20 mg/d
Study: 37870954
Drug: 4-hydroxytamoxifen gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hydroxytamoxifen gel, 2 mg/d per breast
Study: 37870955
Drug: Control (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (investigator's choice of therapy with pembrolizumab, ipilimumab, or dacarbazine)
Study: 37870968
Drug: 960-mg sotorasib-panitumumab
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 960-mg sotorasib-panitumumab
Study: 37870968
Drug: 240-mg sotorasib-panitumumab
Normalized name: sotorasib 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240-mg sotorasib-panitumumab
Study: 37870973
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (platinum-based chemotherapy with or without pembrolizumab)
Study: 37870976
Drug: Amivantamab-chemotherapy
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab-chemotherapy
Study: 37871309
Drug: Enasidenib (ENA)
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enasidenib (ENA) monotherapy
Study: 37871555
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (DT) with dolutegravir or darunavir/cobicistat plus lamivudine
Study: 37871555
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT) with integrase inhibitors
Study: 37871576
Drug: Giroctocogene fitelparvovec
Normalized name: Giroctocogene fitelparvovec
DrugBank: Giroctocogene fitelparvovec (DB16174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giroctocogene fitelparvovec gene therapy (3 × 10^13 vg/kg)
Study: 37871576
Drug: Giroctocogene fitelparvovec
Normalized name: Giroctocogene fitelparvovec
DrugBank: Giroctocogene fitelparvovec (DB16174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giroctocogene fitelparvovec gene therapy
Study: 37871604
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg combined with trastuzumab plus fluoropyrimidine and platinum-based chemotherapy
Study: 37871604
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with trastuzumab plus fluoropyrimidine and platinum-based chemotherapy
Study: 37871608
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus bevacizumab (1200 mg atezolizumab plus 15 mg/kg bevacizumab every 3 weeks for 17 cycles)
Study: 37871703
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) + Enfortumab vedotin (EV) administered on days 1 + 8 of a 21-day cycle until progression or unacceptable toxicity.
Study: 37871703
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) 8 mg/kg with Enfortumab vedotin (EV) 1.25 mg/kg with granulocyte colony-stimulating factor support; MTDs are SG 10 mg/kg with EV 1.25 mg/kg.
Study: 37871841
Drug: No Margin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Margin Treatment (Control)
Study: 37872020
Drug: Toripalimab plus
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab plus axitinib (240 mg intravenously once every 3 weeks + 5 mg orally twice daily)
Study: 37872020
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg orally once daily for 4 weeks or 2 weeks)
Study: 37872225
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose level (DL) treatment
Study: 37872639
Drug: Adolescent survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent survey on discussions about safe use of pain medications
Study: 37873555
Drug: Enpatoran 50
Normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enpatoran 50 mg
Study: 37873555
Drug: Enpatoran 100
Normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enpatoran 100 mg
Study: 37873786
Drug: Oncolytic reovirus
Normalized name: Reovirus type 3 dearing oncolytic virus without transgenes
DrugBank: Pelareorep (DB17284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oncolytic reovirus treatment administered for 5 days every 28 days.
Study: 37873863
Drug: MEDI7247 (pyrrolobenzodiazepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI7247 (pyrrolobenzodiazepine antibody-drug conjugate)
Study: 37874619
Drug: Self-administered on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered on the tablet app using a chatbot interface
Study: 37874619
Drug: Administered by
Normalized name: COVID-19 testing administered by pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by an in-person clinician
Study: 37874619
Drug: Administered by
Normalized name: COVID-19 testing administered by pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by a telehealth clinician
Study: 37874908
Drug: TAVR +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAVR + medical therapy
Study: 37874913
Drug: Immunochemotherapy (mostly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy (mostly R-CHOP 75% and reduced dose R-CHOP 13%)
Study: 37875144
Drug: Neoadjuvant cemiplimab
Normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant cemiplimab 350 mg intravenously every 3 weeks followed by curative-intent surgery
Study: 37875323
Drug: Zimberelimab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimberelimab (240 mg every 2 weeks for 2 years)
Study: 37875559
Drug: Probiotic compound
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic compound AB001 at single dose
Study: 37875559
Drug: Probiotic compound
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic compound AB001 at double dose
Study: 37875578
Drug: zuranolone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: zuranolone 50 mg co-initiated with standard-of-care antidepressant therapy (ADT)
Study: 37875578
Drug: placebo co-initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo co-initiated with standard-of-care antidepressant therapy (ADT)
Study: 37875637
Drug: Chewable beetroot-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable beetroot-based supplement (BR-CT)
Study: 37875771
Drug: Alpelisib in
Normalized name: Product containing alpelisib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib in combination with cetuximab
Study: 37875771
Drug: Alpelisib-cetuximab combination
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alpelisib-cetuximab combination
Study: 37875792
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose enoxaparin (60 mg for 45-60 kg, 80 mg for 61-100 kg, 100 mg for >100 kg) once daily for 14 days, with dose adjustment according to anti-factor Xa activity.
Study: 37875792
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose enoxaparin (IC)
Study: 37875792
Drug: Observational cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational cohort (OC) receiving enoxaparin 40 mg/day
Study: 37875813
Drug: Oral microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral microbiota model for SAP patients
Study: 37875856
Drug: Tango-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tango-therapy
Study: 37875869
Drug: PIPAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC with cisplatin (10.5 mg/m2 in 150 mL NaCl 0.9%) and doxorubicin (2.1 mg/m2 in 50 mL NaCl 0.9%) followed by 2 cycles of FOLFOX every 6-7 weeks (total of 3 PIPACs and 6 cycles of FOLFOX).
Study: 37875943
Drug: VHW-led, CDSS-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: VHW-led, CDSS-assisted T2D care model including lifestyle counselling, first-line oral antidiabetic, lipid-lowering, and antiplatelet treatment guided by a tablet-based CDSS.
Study: 37875997
Drug: Conbercept intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conbercept intravitreal injection (IVC)
Study: 37876018
Drug: HoNOS-13 questionnaire
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HoNOS-13 questionnaire (13-item version including medication compliance)
Study: 37876046
Drug: Damoctocog alfa
Normalized name: DAMOCTOCOG ALFA PEGOL
DrugBank: Damoctocog alfa pegol (DB14700)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Damoctocog alfa pegol (prophylaxis every 3-4 days, median infusion dose of 37.5 IU/kg)
Study: 37876540
Drug: Pasireotide monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide monotherapy
Study: 37876540
Drug: Pasireotide monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide monotherapy and combination therapy
Study: 37876886
Drug: Acacia 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acacia 5 g daily
Study: 37876886
Drug: Acacia 10
Normalized name: ACACIA 1000 [PNU] in 1 mL INTRADERMAL INJECTION, SOLUTION [ACACIA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acacia 10 g daily
Study: 37876886
Drug: Microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose (MCC) 10 g daily
Study: 37876886
Drug: All dietary
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dietary treatment arms (Acacia 5 g/d, Acacia 10 g/d, MCC)
Study: 37876998
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ULDCT)
Study: 37877219
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of ZF2001 after 3-4 months
Study: 37877219
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of ZF2001 after 5-6 months
Study: 37877219
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of ZF2001 after 7-9 months
Study: 37877260
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg/kg
Study: 38907342
Drug: Selumetinib treatment
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib treatment
Study: 37878295
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) in addition to optimal medical therapy
Study: 37878624
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + Plerixafor
Study: 37878675
Drug: PRGN-2012 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRGN-2012 treatment at the highest dose
Study: 37878675
Drug: PRGN-2012 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRGN-2012 treatment
Study: 37878786
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT (n=1426)
Study: 37879047
Drug: Axicabtagene ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axicabtagene ciloleucel (axi-cel) infusion (2 × 10^6 CAR T cells per kg) after leukapheresis and lymphodepleting chemotherapy
Study: 37879047
Drug: Axicabtagene ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axicabtagene ciloleucel (axi-cel) infusion
Study: 37879077
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin administered at 0.6 mg/m2 on day 1 and 0.3 mg/m2 on day 8 of cycle 1, then at 0.3 mg/m2 on days 1 and 8 of cycles 2-6.
Study: 37879242
Drug: Virtual-reality exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual-reality exposure treatment (VRET)
Study: 37879393
Drug: Returning genetic
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Returning genetic results on arsenic metabolism efficiency to inefficient metabolizers (high-risk)
Study: 37879393
Drug: Returning genetic
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Returning genetic results on arsenic metabolism efficiency to efficient metabolizers (low-risk)
Study: 37879536
Drug: Ivonescimab 10
Normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivonescimab 10 mg/kg Q3W
Study: 37879536
Drug: Ivonescimab 20
Normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivonescimab 20 mg/kg Q2W
Study: 37879536
Drug: Ivonescimab 20
Normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivonescimab 20 mg/kg Q3W
Study: 37879536
Drug: Ivonescimab 30
Normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivonescimab 30 mg/kg Q3W
Study: 37879536
Drug: Ivonescimab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivonescimab (all doses)
Study: 37879695
Drug: ASTX727 (demethylating
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX727 (demethylating agent)
Study: 37879701
Drug: Psychoeducation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducation intervention for family carers (administered in 2-hour sessions over 9 weeks)
Study: 37880076
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy for patients with longitudinal undetectable MRD
Study: 37880168
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of LMWH (group C)
Study: 37880581
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral thiamine treatment for chronic fatigue
Study: 37880682
Drug: Metabolism-related prognostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolism-related prognostic model; validated using multiple external datasets.
Study: 37880682
Drug: Metabolism-related prognostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolism-related prognostic model.
Study: 37880704
Drug: High albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High albumin levels (> 36 g/L)
Study: 37880931
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy before pregnancy
Study: 37881307
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of anti-TNF (adalimumab 160mg) followed by a second injection of adalimumab 80mg 2-3 weeks later.
Study: 37881307
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (saline [0.9% sodium chloride]) followed by a second injection of equivalent volume of placebo 2-3 weeks later.
Study: 37882059
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - Estradiol valerate (1 mg) + Medroxyprogesterone acetate (2.5 mg)
Study: 37882706
Drug: 3-week nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3-week nab-paclitaxel (125 mg/m2 on days 1 and 8)
Study: 37882706
Drug: 4-week nab-paclitaxel
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week nab-paclitaxel (125 mg/m2 on days 1, 8, and 15)
Study: 37882974
Drug: First subsequent
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First subsequent therapy
Study: 37883073
Drug: Biweekly cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biweekly cabazitaxel (CBZ16), 16 mg/m2 plus G-CSF and daily prednisolone
Study: 37883073
Drug: Triweekly cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triweekly cabazitaxel (CBZ25), 25 mg/m2 plus G-CSF and daily prednisolone
Study: 37883081
Drug: Antiangiogenic metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic metronomic therapy (daily oral thalidomide, fenofibrate, celecoxib, alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide, intravenous bevacizumab, intraventricular therapy with alternating etoposide and cytarabine)
Study: 37883081
Drug: Antiangiogenic metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic metronomic therapy
Study: 37883128
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT) via telehealth
Study: 37883128
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT) in-office
Study: 37883128
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT) in-home
Study: 37883190
Drug: Low initial
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low initial myocardial 18F-dopamine-derived radioactivity (<6,000 nCi-kg/cc-mCi)
Study: 37883329
Drug: Microtubule-targeted agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microtubule-targeted agents
Study: 37883329
Drug: Drug that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug that increases CIN
Study: 37883413
Drug: Medicine Information
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine Information Helpline (MIH)
Study: 37883723
Drug: Biomarker group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker group (specific targeted agents plus paclitaxel)
Study: 37883727
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin induction therapy
Study: 37883739
Drug: Response-Adjusted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-Adjusted Therapy
Study: 37883738
Drug: Total Neoadjuvant
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Neoadjuvant Therapy
Study: 37883795
Drug: CAR-T cells
Normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T cells (CTL019) with time-limited ibrutinib, started before leukapheresis and continued for a minimum of 6 months post-CAR-T administration.
Study: 37883802
Drug: rFXIII-A2 infusion
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFXIII-A2 infusion
Study: 37883997
Drug: Cryocompression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryocompression therapy on dominant hand and foot
Study: 37883997
Drug: Cryocompression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryocompression therapy
Study: 37884337
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) stimulation as an adjunct therapy to lumbar spinal fusion procedures
Study: 37884680
Drug: Digital lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital lifestyle treatment
Study: 37884972
Drug: Short-chain fatty
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-chain fatty acids (SCFAs) - acetate, propionate, butyrate delivered via pH-dependent colon-delivery capsules for six weeks
Study: 37885026
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (IVI) - ferric derisomaltose
Study: 37885233
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine Sodium Soft Gelatin Capsules
Study: 37885445
Drug: Multi-ingredient herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-ingredient herbal supplement (12 weeks)
Study: 37885795
Drug: Primary series
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary series (2 doses)
Study: 37885795
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose (monovalent)